CA2089488A1 - Agent pathogene pour therapie cytotoxique - Google Patents
Agent pathogene pour therapie cytotoxiqueInfo
- Publication number
- CA2089488A1 CA2089488A1 CA002089488A CA2089488A CA2089488A1 CA 2089488 A1 CA2089488 A1 CA 2089488A1 CA 002089488 A CA002089488 A CA 002089488A CA 2089488 A CA2089488 A CA 2089488A CA 2089488 A1 CA2089488 A1 CA 2089488A1
- Authority
- CA
- Canada
- Prior art keywords
- pathogen
- cells
- infected
- ctl
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 67
- 244000052769 pathogen Species 0.000 title claims abstract description 64
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 70
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 19
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 18
- 230000003834 intracellular effect Effects 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 84
- 241000124008 Mammalia Species 0.000 claims description 36
- 230000002934 lysing effect Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 abstract description 2
- 230000001472 cytotoxic effect Effects 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 45
- 210000001744 T-lymphocyte Anatomy 0.000 description 29
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102100034343 Integrase Human genes 0.000 description 12
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 241000700605 Viruses Species 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 206010046865 Vaccinia virus infection Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 208000007089 vaccinia Diseases 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 108010074338 Lymphokines Proteins 0.000 description 4
- 102000008072 Lymphokines Human genes 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 101710192141 Protein Nef Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710145242 Minor capsid protein P3-RTD Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1991/006441 WO1992004462A1 (fr) | 1990-09-06 | 1991-09-06 | Therapie par cellules t cytotoxiques (ctl) specifiques d'agents pathogenes |
| EP91918302A EP0547166A1 (fr) | 1990-09-06 | 1991-09-06 | Therapie par cellules t cytotoxiques (ctl) specifiques d'agents pathogenes |
| AU87379/91A AU660422B2 (en) | 1990-09-06 | 1991-09-06 | Pathogen-specific CTL therapy |
| CA002089488A CA2089488A1 (fr) | 1990-09-06 | 1991-09-06 | Agent pathogene pour therapie cytotoxique |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57882890A | 1990-09-06 | 1990-09-06 | |
| PCT/US1991/006441 WO1992004462A1 (fr) | 1990-09-06 | 1991-09-06 | Therapie par cellules t cytotoxiques (ctl) specifiques d'agents pathogenes |
| CA002089488A CA2089488A1 (fr) | 1990-09-06 | 1991-09-06 | Agent pathogene pour therapie cytotoxique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2089488A1 true CA2089488A1 (fr) | 1993-03-07 |
Family
ID=25675897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002089488A Abandoned CA2089488A1 (fr) | 1990-09-06 | 1991-09-06 | Agent pathogene pour therapie cytotoxique |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0547166A1 (fr) |
| AU (1) | AU660422B2 (fr) |
| CA (1) | CA2089488A1 (fr) |
| WO (1) | WO1992004462A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346989A (en) * | 1990-08-22 | 1994-09-13 | Syntello Vaccine Development Kb | Peptides for use in induction of T cell activation against HIV-1 |
| WO1992021377A1 (fr) * | 1991-06-03 | 1992-12-10 | Syntello Inc. | Peptides a utiliser pour induire l'activation de lymphocytes t contre le vih-1 |
| US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
| WO1995014713A2 (fr) | 1993-11-23 | 1995-06-01 | The Regents Of The University Of California | Vaccins a base de produits extracellulaires abondants, leurs procedes de fabrication et leur utilisation |
| US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| WO1997007128A1 (fr) * | 1995-08-21 | 1997-02-27 | Duke University | Procede pour accroitre la densite d'un antigene sur une cellule presentant un antigene |
| US5994308A (en) | 1996-02-28 | 1999-11-30 | Board Of Trustees Of Southern Illinois University | Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use |
| US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
| DE19710496A1 (de) * | 1997-03-13 | 1998-09-17 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis antigenspezifischer T-Zellen nach Anreicherung von mononukleären Zellpopulationen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0260714B1 (fr) * | 1986-09-19 | 1994-06-29 | Oncogen Limited Partnership | Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA |
-
1991
- 1991-09-06 CA CA002089488A patent/CA2089488A1/fr not_active Abandoned
- 1991-09-06 EP EP91918302A patent/EP0547166A1/fr not_active Ceased
- 1991-09-06 AU AU87379/91A patent/AU660422B2/en not_active Ceased
- 1991-09-06 WO PCT/US1991/006441 patent/WO1992004462A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU8737991A (en) | 1992-03-30 |
| EP0547166A4 (fr) | 1994-03-09 |
| AU660422B2 (en) | 1995-06-29 |
| WO1992004462A1 (fr) | 1992-03-19 |
| EP0547166A1 (fr) | 1993-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes | |
| Perez et al. | An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. | |
| Castro et al. | Suppression of human immunodeficiency virus replication by CD8+ cells from infected and uninfected chimpanzees | |
| Moris et al. | Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer | |
| US5081029A (en) | Methods of adoptive immunotherapy for treatment of aids | |
| Klatzmann et al. | HIV infection: facts and hypotheses | |
| Macatonia et al. | Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. | |
| Jacobson et al. | HTLV‐I‐specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV‐I‐associated neurological disease | |
| Dai et al. | Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes | |
| Lusso et al. | Cell-mediated immune response toward viral envelope and core antigens in gibbon apes (Hylobates lar) chronically infected with human immunodeficiency virus-1. | |
| Chehimi et al. | In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates | |
| WO1989005349A1 (fr) | Procede servant a combattre des infections virales | |
| Petit et al. | Nef is required for efficient HIV-1 replication in cocultures of dendritic cells and lymphocytes | |
| JP2020513782A (ja) | Ｈｉｖ感染を治療するキメラ抗原受容体の組換え遺伝子構築およびその応用 | |
| EP0400076B1 (fr) | Antigene synthetique suscitant une reaction anti-vih | |
| Littaua et al. | A CD4+ cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and secretion of interleukin-2 and interleukin-6 | |
| Cheng-Mayer et al. | Altered host range of HIV-1 after passage through various human cell types | |
| AU660422B2 (en) | Pathogen-specific CTL therapy | |
| Benson et al. | Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals | |
| De Maria et al. | CD8+ cytolytic T lymphocytes become infected in vitro in the process of killing HIV‐1‐infected target cells | |
| Lee et al. | Cytotoxic activity against maedi-visna virus-infected macrophages | |
| Clerici et al. | Circumvention of defective CD4 T helper cell function in HIV-infected individuals by stimulation with HLA alloantigens. | |
| LUDEWIG et al. | Transmission of HIV-1 from productively infected mature Langerhans cells to primary CD4+ T lymphocytes results in altered T cell responses with enhanced production of IFN-γ and IL-10 | |
| WO1993014789A1 (fr) | Therapie par lymphocytes t cytotoxiques (ltc) specifiques d'un pathogene | |
| EP0260714B1 (fr) | Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |